ArticleScientific reports2025
mRNA decapping enzyme2 DCP2 expression correlates with progression and prognosis of hepatocellular carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mRNA decapping enzyme 2 (DCP2) is a key regulator of mRNA degradation, influencing RNA metabolism and gene expression. While implicated in various diseases, its role in Hepatocellular carcinoma (HCC) remains unclear. This study explores DCP2 as a potential biomarker for HCC through bioinformatics and experimental analyses. Public databases, including The Cancer Genome Atlas (TCGA) and GEPIA2 online database, revealed significant DCP2 upregulation in HCC tissues, correlating with Tumor-Node-Metastasis (TNM) staging, histological grading, platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and alpha-fetoprotein (AFP) levels. Prognostic analysis confirmed high DCP2 expression as an indicator of poor overall survival (OS). Functional enrichment analyses linked DCP2 to cancer-associated pathways, including PI3K/Akt, Hippo signaling, cholesterol metabolism, and oxidative phosphorylation. Immune infiltration analysis showed significant correlations with tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), suggesting a role in immune modulation. Experimental validation via western blot and immunohistochemistry (IHC) confirmed elevated DCP2 expression in HCC cell lines and tissues. These findings suggest that DCP2 may be involved in HCC progression by influencing mRNA degradation, cancer-related signaling, and the immune microenvironment. Although DCP2 shows potential as a diagnostic and prognostic biomarker, as well as a therapeutic target, further functional studies-such as gene knockdown and overexpression experiments-are needed to confirm its mechanistic role in the development of hepatocellular carcinoma (HCC).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.